Patient RCC Drug Preferences Revealed

Published June 4, 2012

Patient RCC Drug Preferences Revealed

Filed under: Maryland Drug Treatment Centers

20%) as well as fewer treatment interruptions (6% vs. 12%). “While we expected patients would prefer one drug over the other due to the known toxicity profiles, we didn't expect this great a preference,” said lead investigator Bernard J. Escudier, MD, …
Read more on Renal and Urology News

ARIAD Announces Updated Data from Pivotal PACE Trial of Ponatinib, Its …

Filed under: Maryland Drug Treatment Centers

… or who have the T315I mutation for which there are no currently available treatments," stated Jorge Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Read more on MarketWatch (press release)

For Advanced Prostate Cancer, New Drug Slows Disease

Filed under: Maryland Drug Treatment Centers

The researchers say the medication could provide new treatment options. "This drug extended lives and gave patients more time when they weren't experiencing significant pain from the disease,'' said the principal investigator of the international trial …
Read more on Science Daily (press release)